Fischer Medical Ventures LimitedQ1 FY27 Results & Financial Update
Fischer Medical Ventures Limited: Q1 FY27 consolidated results and company financials – revenue ₹81.92 Cr, PAT ₹3.79 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Fischer Medical Ventures price & chart
Market price₹25.03
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Fischer Medical Ventures Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
For the quarter ended June 30, 2026 (Q1 FY27), Fischer Medical Ventures reported consolidated revenue from operations of ₹81.92 crore (₹8,192.00 lakhs) and total consolidated income of ₹83.40 crore.
Profit before tax (PBT) for the quarter stood at ₹7.83 crore (₹783.21 lakhs), reflecting positive operational earnings at the consolidated level.
Consolidated profit for the period (PAT) closed at ₹3.79 crore (₹379.13 lakhs), resulting in a basic earnings per share (EPS) of ₹0.06 and diluted EPS of ₹0.05 for the quarter.
Total consolidated expenses for the period aggregated to ₹75.57 crore, driven primarily by the cost of materials consumed of ₹43.98 crore, purchase of traded goods of ₹22.10 crore, employee benefit expenses of ₹4.52 crore, and finance costs of ₹3.54 crore.
The company noted that it operates primarily in a single reportable business segment in accordance with Ind AS 108 (Operating Segments), and therefore separate segment reporting has not been provided.
Subsequent to the quarter end, the Board of Directors approved multiple equity share allotments via circular resolutions on August 11, August 12, and August 13, 2026, stemming from the conversion of convertible warrants by promoters and non-promoters.
Profit after tax was ₹3.79 Cr for the reported quarter. EPS was ₹0.05 for the reported quarter.
01 · Business model
What does Fischer Medical Ventures do?
Fischer Medical Ventures Limited (formerly known as Fischer Chemic Limited) operates in the medical technology sector, focusing on healthcare devices, diagnostics, and related digital and hospitality services.
The company's operations span a wide network of domestic subsidiaries, foreign subsidiaries, step-down subsidiaries, and associates across India, Singapore, Malaysia, the Philippines, and Indonesia.
Key operating entities within the consolidated corporate structure include Time Medical International Ventures (India) Private Limited, Flynncare HealthCare Innovations Private Limited, Wondertech Medical Solutions Pvt Ltd, and Nanyang Biologics (India) Private Limited, alongside several overseas entities.
The corporate and registered offices are anchored in Visakhapatnam (Andhra Pradesh Medtech Zone) and Chennai, positioning the enterprise within key medical manufacturing and technology hubs.
02 · Historical context
What shaped the business before this quarter
Previously known as Fischer Chemic Limited, the company transitioned its corporate identity to Fischer Medical Ventures Limited to better reflect its core business focus in medical technology and healthcare devices.
During annual audits of certain foreign subsidiaries—namely FMV International Ventures PTE Ltd., Fischer Hospitality Sdn. Bhd., FMV Global Innovations PTE Ltd., Pellucid Care Health Innovations Pte Ltd, and FMV Technologies Sdn Bhd—component auditors identified adjustments relating to earlier quarterly periods, leading to restatements of comparative figures for Q1 FY25 and Q4 FY26.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹81.92 Cr |
| Total income | ₹83.40 Cr |
| Profit before tax | ₹7.83 Cr |
| Profit after tax | ₹3.79 Cr |
| EPS | ₹0.05 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 4.6% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 9.6% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹1.48 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Consolidated revenue from operations for Q1 FY27 reached ₹81.92 crore, backed by the combined performance of domestic and international subsidiaries spanning medical diagnostics, technology, and health innovations.
Other income added ₹1.48 crore (₹148.43 lakhs) to the total consolidated income of ₹83.40 crore for the quarter.
What drove margins
The cost of materials consumed formed the largest expense block at ₹43.98 crore, alongside traded goods purchases of ₹22.10 crore and inventory adjustments of negative ₹7.86 crore.
Employee benefit expenses stood at ₹4.52 crore, finance costs at ₹3.54 crore, depreciation and amortization at ₹1.36 crore, and other expenses at ₹7.93 crore, shaping the consolidated bottom-line outcome.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
In accordance with Ind AS 108, the Group operates in a single reportable business segment covering medical ventures and healthcare solutions; hence, no discrete segment breakdown is provided.
Geography and market mix
The consolidated structure includes foreign subsidiaries and step-down entities operating across Singapore, Malaysia, Indonesia, and the Philippines, contributing to international revenues and asset pools.
06 · Reported developments
What changed operationally
The company reported a consolidated net profit after tax of ₹3.79 crore for Q1 FY27, supported by stable operational performance across its subsidiaries.
07 · Pressure points & risks
What is not going smoothly
Independent Directors Mr. Roberto M Pagdanganan and Mr. Sanjay Jayantilal Jain tendered their resignations effective August 14, 2026, citing personal reasons and professional commitments.
08 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Capital allocation & funding
In August 2026, the board approved equity share allotments aggregating over ₹40.72 crore across multiple tranches upon the conversion of convertible warrants by promoter entities (including Shankar Varadharajan and FMV Holdings Pte Ltd) and non-promoter allottees (Roopal Hitesh Kawa) at an issue price of ₹23.40 per share.
09 · Beyond the numbers
What changed beyond the numbers
Reported update
Board Committee Reconstitution
Following the resignation of independent directors, the company reconstituted its Audit Committee and Nomination and Remuneration Committee, appointing Mr. Khairy Jamaluddin Abu Bakar as Chairman of both committees.
10 · Previous-quarter changes
What changed since the previous quarter
Consolidated financial statements incorporated adjustments to comparative figures for prior quarters following annual audit findings from component auditors of foreign subsidiaries.
11 · Key Q&A
The quarter, answered directly
What does Fischer Medical Ventures do?
Fischer Medical Ventures Limited (formerly known as Fischer Chemic Limited) operates in the medical technology sector, focusing on healthcare devices, diagnostics, and related digital and hospitality services.
What is the clearest takeaway from Q1 FY27?
For the quarter ended June 30, 2026 (Q1 FY27), Fischer Medical Ventures reported consolidated revenue from operations of ₹81.92 crore (₹8,192.00 lakhs) and total consolidated income of ₹83.40 crore.
What drove revenue or demand?
Consolidated revenue from operations for Q1 FY27 reached ₹81.92 crore, backed by the combined performance of domestic and international subsidiaries spanning medical diagnostics, technology, and health innovations.
What mattered most for margins or profitability?
The cost of materials consumed formed the largest expense block at ₹43.98 crore, alongside traded goods purchases of ₹22.10 crore and inventory adjustments of negative ₹7.86 crore.
What changed operationally beyond the headline numbers?
Following the resignation of independent directors, the company reconstituted its Audit Committee and Nomination and Remuneration Committee, appointing Mr. Khairy Jamaluddin Abu Bakar as Chairman of both committees.
What are the main pressure points disclosed for the quarter?
Independent Directors Mr. Roberto M Pagdanganan and Mr. Sanjay Jayantilal Jain tendered their resignations effective August 14, 2026, citing personal reasons and professional commitments.
12 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
13 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Integration of Warrant Capital: Monitor the deployment of capital raised through the conversion of convertible warrants totaling over ₹40 crore across August 2026 allotments.
- 02
Subsidiary Performance Tracking: Track ongoing financial contributions from international subsidiaries and step-down entities across Southeast Asia.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.